Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma

In a phase II trial of nivolumab in advanced thymic carcinoma (UMIN000022007), long SD (SD for more than 24 weeks) was seen in three patients and irAE (Gr2 or higher) was seen in four patients among 15 patients. Here, we report preplanned comprehensive biomarker analyses. We obtained tumor samples for immunohistochemistry, peripheral blood mononuclear cells (PBMCs), plasma and serum for pharmacokinetic analysis of nivolumab and cytokine evaluations, and whole blood for immuno pharmacogenomic (PGx) analysis. PD-L1 expression on tumor cells were not associated with therapeutic efficacy, but FOXP3 expression in tumor area and stroma, CD204 expression in stroma, and MHC class I in tumor area were all low among long SD patients. PBMC of long SD patients presented with larger number of naïve/memory cells prior to treatment, suggesting priming after nivolumab administration. Immuno-PGx analysis showed non-synonymous SNVs in ITGAX and PDCD1 had some correlation with PFS. Concentration of nivolumab in blood during the treatment was not related to PFS, with their overall trend towards decreased nivolumab concentration in patients with irAEs. Low immunogenicity of thymic carcinoma demonstrated in our study may require the activation of immune systems via a combination of immune checkpoint blockades.

[1]  C. Pritchard,et al.  Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy , 2021, Journal for ImmunoTherapy of Cancer.

[2]  R. Scolyer,et al.  PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma , 2021, Frontiers in Immunology.

[3]  E. Jonasch,et al.  High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Mansfield,et al.  First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial , 2021, The Lancet.

[5]  Kazuaki Matsumoto,et al.  Use of an alternative signature peptide during development of a LC-MS/MS assay of plasma nivolumab levels applicable for multiple species. , 2020, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  J. Aerts,et al.  Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials , 2020, EBioMedicine.

[7]  G. Argenziano,et al.  Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients , 2020, Scientific Reports.

[8]  Y. Ohe,et al.  CD20+ tumor‐infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma , 2020, Cancer science.

[9]  K. Muro,et al.  Immune monitoring of blood in advanced gastroesophageal adenocarcinoma patients treated with an anti-MMP9 monoclonal antibody in combination with nivolumab. , 2020 .

[10]  K. Horimoto,et al.  CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy , 2019, Cancer Immunology Research.

[11]  S. Okuno,et al.  Immunotherapy in breast cancer , 2019, Journal of carcinogenesis.

[12]  Y. Hosomi,et al.  Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. , 2019, European journal of cancer.

[13]  J. Madore,et al.  Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. , 2019, Cancer cell.

[14]  Yukiko Nakamura,et al.  Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing. , 2019, Lung cancer.

[15]  Edmond J. Breen,et al.  Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy , 2018, Clinical Cancer Research.

[16]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[17]  M. Yamashita,et al.  Biomarkers for Immune Checkpoint Inhibitors in Melanoma , 2018, Front. Oncol..

[18]  G. Giaccone,et al.  Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. , 2018, The Lancet. Oncology.

[19]  Benjamin J. Raphael,et al.  The Integrated Genomic Landscape of Thymic Epithelial Tumors. , 2018, Cancer cell.

[20]  Roberta Losi Guembarovski,et al.  Interleukin 7 receptor alpha Thr244Ile genetic polymorphism is associated with susceptibility and prognostic markers in breast cancer subgroups , 2017, Cytokine.

[21]  T. Kohno,et al.  The genomic and epigenomic landscape in thymic carcinoma , 2017, Carcinogenesis.

[22]  H. Wakui,et al.  Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors , 2016, Investigational New Drugs.

[23]  Z. Dai,et al.  PD-1 rs2227982 Polymorphism Is Associated With the Decreased Risk of Breast Cancer in Northwest Chinese Women , 2016, Medicine.

[24]  A. Kijlstra,et al.  Genetic polymorphisms of cell adhesion molecules in Behcet’s disease in a Chinese Han population , 2016, Scientific Reports.

[25]  H. Gu,et al.  Programmed death-1 (PD-1) polymorphism is associated with gastric cardia adenocarcinoma. , 2015, International journal of clinical and experimental medicine.

[26]  D. Bang,et al.  CD11a, CD11c, and CD18 gene polymorphisms and susceptibility to Behçet's disease in Koreans. , 2014, Tissue antigens.

[27]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[28]  P. Gregersen,et al.  Evaluation of imputation-based association in and around the integrin-alpha-M (ITGAM) gene and replication of robust association between a non-synonymous functional variant within ITGAM and systemic lupus erythematosus (SLE). , 2009, Human molecular genetics.